Frequency of <i>KLK3 </i>gene deletions in the general population by Rodriguez, Santi et al.
                          Rodriguez, S., Alghamdi, O., Guthrie, P., Shihab, H., McArdle, W., Gaunt,
T., ... Day, I. (2016). Frequency of KLK3 gene deletions in the general
population. Annals of Clinical Biochemistry. DOI:
10.1177/0004563216666999
Peer reviewed version
Link to published version (if available):
10.1177/0004563216666999
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Sage at http://journals.sagepub.com/doi/10.1177/0004563216666999. Please refer to any applicable terms
of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms.html
1 
 
Frequency of KLK3 gene deletions in the general population 
 
Short title: Frequency of KLK3 deletions 
 
Santiago Rodriguez1†*, Osama A. Al-Ghamdi2,3†, Philip A. I. Guthrie1, Hashem A. Shihab1, 
Wendy McArdle3, Tom Gaunt1, Khalid K. Alharbi2, and Ian N. M. Day3 
 
1 MRC Integrative Epidemiology Unit (IEU), School of Social and Community Medicine, 
University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK 
2 Clinical Laboratory Sciences Department, College of Applied Medical Sciences, King Saud 
University, P. O. Box 10219, Riyadh 11433, Saudi Arabia 
3 School of Social and Community Medicine, University of Bristol, Oakfield House, Oakfield 
Grove, Bristol BS8 2BN, UK 
 
† Equal first authorship 
 
* To whom correspondence should be addressed: Santiago Rodriguez, MRC Integrative 
Epidemiology Unit (IEU), School of Social and Community Medicine, University of Bristol, 
Oakfield House, Oakfield Grove, Bristol BS8 2BN, United Kingdom. Tel: +44 01173310133; 
Email: santi.rodriguez@bristol.ac.uk 
 
Word count: 2850 
 
COMPETING INTERESTS 
 
2 
 
The authors declare that they have no competing interests. 
 
FUNDING 
 
This work was supported by an overseas PhD studentship from King Saud University 
(Riyadh, Saudi Arabia) to Osama Al-Ghamdi. Funding for the project was provided by the 
Wellcome Trust under award 076113 and 085475. The Integrative Epidemiology Unit is 
supported by the MRC and the University of Bristol (MC_UU_12013/1-9). 
 
ETHICAL APPROVAL  
 
Ethical approval was obtained from the South East, UK, Multi-centre Research Ethics 
Committee (reference 01/1/44). 
 
ACKNOWLEDGEMENTS 
 
This work was supported by an overseas PhD studentship from King Saud University 
(Riyadh, Saudi Arabia) to Osama Al-Ghamdi. This study makes use of data generated by the 
Wellcome Trust Case-Control Consortium. A full list of the investigators who contributed to 
the generation of the data is available from www.wtccc.org.uk. Funding for the project was 
provided by the Wellcome Trust under award 076113 and 085475. The Integrative 
Epidemiology Unit is supported by the MRC and the University of Bristol 
(MC_UU_12013/1-9).
3 
 
ABSTRACT 
 
BACKGROUND: One of the kallikrein genes (KLK3) encodes Prostate Specific Antigen 
(PSA), a key biomarker for prostate cancer. A number of factors, both genetic and non-
genetic, determine variation of serum PSA concentrations in the population. We have 
recently found three KLK3 deletions in individuals with very low PSA levels, suggesting a 
link between abnormally reduced KLK3 expression and deletions of KLK3. Here we aim to 
determine the frequency of kallikrein gene 3 deletions in the general population. METHODS: 
The frequency of KLK3 deletions in the general population was estimated from the 1958 
Birth Cohort sample (N=3815) using ARCS (Amplification Ratiometry Control System). In 
silico analyses using PennCNV were carried out in the same cohort and in NBS-WTCCC2 in 
order to provide an independent estimation of the frequency of KLK3 deletions in the general 
population. RESULTS: ARCS results from the 1958 cohort indicated a frequency of KLK3 
deletions of 0.81% (3.98% following a less stringent calling criterion). From in silico 
analyses, we found that potential deletions harbouring the KLK3 gene occurred at rates of 
2.13% (1958 Cohort, N=2867) and 0.99% (NBS-WTCCC2, N=2737) respectively. These 
results are in good agreement with our in vitro experiments. All deletions found were in 
heterozygosis. CONCLUSIONS: We conclude that a number of individuals from the general 
population present KLK3 deletions in heterozygosis. Further studies are required in order to 
know if interpretation of low serum PSA concentrations in individuals with KLK3 deletions 
may offer false negative assurances with consequences for prostate cancer screening, 
diagnosis and monitoring. 
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INTRODUCTION 
 
Prostate Specific Antigen (PSA) is a key biomarker for prostate cancer (PCa) diagnosis and 
monitoring, and has been advocated for PCa screening.1 PSA is encoded by KLK3, a 
kallikrein gene.2 Several studies have associated serum PSA concentrations with KLK3 
SNPs.3 Most of the associations in the pre-Genome Wide Association Studies (GWAS) era 
were insufficiently replicated. However, recent GWAS4-6 with higher power have reinforced 
a number of previous associations, in addition to discovering new variants linked with 
circulating PSA.  
 
We have previously analysed the presence of inactivating genetic variants in KLK3 that 
would be consistent with haploinsufficient levels of PSA.7 A thorough analysis was done to 
investigate KLK3 variants at the DNA sequence and at the structural levels from the study of 
thirty individuals with the lowest PSA concentrations (≤0.1 ng/mL) and absence of PCa 
among 85,000 men from the ProtecT biorepository.7 This report was the only study to date 
that detected the presence of hemizygous deletions in three individuals with very low levels 
of PSA, representing a likely link between KLK3 deletions and low PSA concentrations.7 
These individuals had no diagnosis of PCa. However, other (affected) individuals with these 
genetic rearrangements may be misidentified as PCa-free due to their impaired ability to 
express PSA.  
 
PCR-based methods have prevailed as the tools of choice for the targeted screening of Copy 
Number Variants (CNVs), due to their rapidity, simplicity and flexibility. Several techniques 
employ PCR in a multiplex manner, as a means to enhance gene dosage estimation by co-
amplifying reference genes along with ones in test. Examples include multiplex polymerase 
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chain reaction of short fluorescent fragments,8 multiplex amplifiable probe hybridisation 
(MAPH),9 multiplex ligation-dependent probe amplification (MLPA),10 the paralogue ratio 
test (PRT)11 and quantitative real time PCR (qPCR), in addition to the methodology used in 
this study: the amplification ratiometry control system (ARCS).12 Apart from ARCS, all of 
these methods have been  reviewed at length 13 and a useful comparison of performance 
characteristics across these PCR-based tests for copy number is available.12  
 
Gross rearrangements can also be detected by in silico approaches. It is known that the 
agreement between both in silico and experimental approaches is important for CNV 
validation.14 
 
SNP arrays were originally designed to genotype SNPs for GWAS; however they have been 
adapted for structural variant discovery from large datasets. Several generations of dense 
SNP array platforms have been made available by leading companies in the industry (e.g. 
Illumina and Affymetrix), motivating the development of several algorithms (e.g. PennCNV) 
that normalise key metrics like signal probe intensities and minor allele frequencies from 
various forms of genetic data, to detect copy number variants. 
 
PennCNV employs hidden Markov models to infer the underlying states of copy number 
while interrogating multiple features, two of which are key in CNV detection. The B Allele 
Frequency (BAF) value is a measure of the allelic intensity (i.e. proportions of the B allele 
compared to the A allele), whereas Log R Ratio (LRR) is an indicator of signal intensity. 
PennCNV has been previously used to detect CNVs in genomic regions.15; 16 
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The characterisation of the frequency of KLK3 deletions in the general population is relevant 
to the knowledge of their implications for the use of PSA as a biomarker for the detection of 
PCa, in addition to monitoring its progression, and guiding treatment. Our aim in this study 
was to estimate the frequency of KLK3 deletions in the general population from both in vitro 
and in silico data. 
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MATERIALS AND METHODS 
 
WTCCC2 studies: the 1958BC and the NBS samples 
 
The National Child Development Study (NCDS), otherwise known as the 1958 British birth 
cohort (1958BC) started as a perinatal mortality and morbidity survey, looking at all births in 
England, Wales and Scotland in a single week in 1958. This included an original sample of 
17,638 births (in addition to a further 920 immigrants born in the same reference week). 
Cohort members were further followed-up by medical examinations (at 7, 11 and 16 years of 
age) and interviews (at ages 23, 33 and 42). The first biomedical assessment was conducted 
between September 2002 and March 2004 by trained nurses from the National Centre for 
Social Research, who visited the homes of cohort members at age 44-45 years.17, 18  
 
Consent was sought to collect blood samples for the extraction and storage of DNA and the 
creation of immortalised cell lines (via Epstein-Barr viral transformation of peripheral blood 
lymphocytes) for research purpose. A final set of 8018 EDTA blood samples, in addition to 
7526 successfully transformed cell cultures were used to derive two DNA sample series of 
peripheral blood and cell line origin respectively 
[http://www2.le.ac.uk/projects/birthcohort/1958bc/available-resources]. These efforts led to 
the creation of a national research resource through funds from the Wellcome Trust and The 
Medical Research Council.18 
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A subset of 3000 controls from the 1958BC, in addition to 3000 samples from the UK 
National Blood Service (NBS) were genotyped using cell line DNA by the WTCCC2 
(Wellcome Trust Case Control Consortium, second round) in WTCCC2 project controls 
study (Study ID EGAS00000000028). The 6000 controls were genotyped on both the 
Illumina 1.2M and the Affymetrix v6.0 chips [http://www.wtccc.org.uk/ccc2/].  
 
Ethical approval was obtained from the South East, UK, Multi-centre Research Ethics 
Committee (reference 01/1/44). 
 
ARCS assays to estimate the frequency of KLK3 deletions in the 1958 cohort 
 
A high-throughput ratiometric method (ARCS) developed and validated in our laboratory,12 
was used to identify KLK3 deletions. This approach has previously been used to detect KLK3 
deletions in individuals with very low PSA levels.7 In short, it is based on a PCR protocol 
which analyses the ratio of copy-number-variable target gene to diploid (2n)-copy reference 
gene. The target and reference gene amplicons are designed to have melting temperatures 
separated by a few degrees to enable differentiation in a melt assay, and the ratio of target 
copy number to reference is derived from the change in fluorescence contributed by each as it 
undergoes melting. 
 
Rodriguez et al,7 showed that KLK3 exon 3 is a good indicator of KLK3 deletions, since it 
was deleted in all three individuals showing KLK3 deletions. Copy number status was 
surveyed for a total of 3815 cell line DNA samples from the 1958 cohort by ARCS at KLK3 
exon 3. Beta globin (HBB), an established reference for ARCS assays in our lab, was used as 
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the reference for diploid number. The assays were run in duplicates for each sample. ARCS 
primers and conditions were as previously described.7  
 
Statistical analysis of data from ARCS  
 
An in-house Perl script written by Guthrie et al12 was used to calculate peak heights. This 
script analyses melt files (.mlt) from the LightTyper (Roche Diagnostics Corporation, 
Indianapolis, Indiana, USA), generating cluster plots to enable the visualisation of potential 
copy number classes. Further output lists well position, left (L) peak height, right (R) peak 
height, (L/R) peak height ratio and fluorescence intensity per well in spreadsheet format. 
These were saved for further statistical analyses. 95% confidence intervals were calculated to 
assign copy number, as follows: In ARCS, target peak height/reference peak height ratios are 
calculated to infer copy number, after which the mean ARCS ratio (a plate specific attribute) 
for all of the samples in a run is calculated.  
 
In the original implementation of ARCS, the left peak was for a target gene (HP), while the 
right peak was for a reference amplicon (TP53). Deletions or duplications will have ratios 
lower or higher than 1.96SDs from the mean ratio –respectively-. Whereas, in the KLK3 
assays described above, this order was flipped, assigning the left peak for the AT-rich 
reference amplicons HBB, whereas the right peak represents the target (KLK3 exon 3) (higher 
in GC content). This would make the height of the target peak the denominator in calculated 
ratios, and thus renders it inversely proportional to the ARCS ratios (i.e. deletions will have 
higher ratios than duplications).  
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Samples with values that lie outside the ±1.96SDs of the mean target peak height/reference peak 
height are flagged as potential CNVs. ARCS assays were designed to test KLK3 exons 3 
(conditions in supplementary file).  
 
PennCNV software to estimate the frequency of KLK3 deletions in the 1958 and NBS 
cohorts 
 
We used the Illumina dataset (ega Dataset ID EGAD00000000022). All of the data from 
iDAT files corresponding to ≈3000 samples from each cohort were compacted into 13 final 
reports per dataset. These reports contained all of the essential probe intensity data needed by 
PennCNV.19 PennCNV, initially built to analyse Illumina genotyping data is capable of 
handling Affymetrix data through its alternative version PennCNV-Affy. In general, for an 
algorithm developed to analyse data from a specific platform, its performance is more 
powerful when applied to data from the same format and shows some weakness when applied 
to another platform.14 In addition, algorithm-specific platforms are more specific than 
platform-independent software.20 
 
Individual exclusions criteria  
 
A comprehensive set of genotypes, intensities and signal data were provided for the 1958BC 
and the NBS controls datasets. Individual exclusions from the initial 3000 samples in each set 
were based on some of the following considerations: (i) Based on a principal component 
analysis (PCA) of HapMap individuals, samples that differed from the majority of the 
collection in terms of ancestry were excluded. The final datasets within the WTCCC2 project 
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controls study included genotypes from the 1958BC (n=2867) and NBS (n=2737) after 
initially drawing 3000 DNA samples in each of the two cohorts. (ii) Gender discrepancies 
between sex reported by suppliers and sex estimated from normalising A-allele probes on the 
X chromosome to autosomal intensities. (iii) Disproportionate missingness or heterozygosity 
compared to the cohort-wide fraction of called SNPs that were missing or heterozygous 
respectively. (iv) Identity by descent (IBD) at 5% or higher, identified by a hidden Markov 
model (HMM). (v) Identity checks. Prior to full genotyping, individuals were genotyped by 
Sequenom at a reference panel of 30 SNPs via the Wellcome Trust Sanger Institute (WTSI). 
Samples with concordance of less than 90% between Sequenom and full genotypes were 
deemed unknown and thus excluded. (vi) Batch effects. The cohort-wide mean of the A and 
B allele intensities from 10000 SNPs on chromosome 22 was computed and outliers were 
excluded. 
In addition, exclusions regarding SNPs included minor allele frequency less than 0.01, 
violation of Hardy-Weinberg equilibrium (HWE) at < 1e-20 and genotyping missingness of 
2% or more at the SNPs that reach the maximum call probability threshold. 
 
Statistical analysis of data from PennCNV 
 
The combination of LRR and BAF values was used to estimate KLK3 deletion frequencies in 
two large samples by PennCNV. 
 
The two essential metrics to infer copy number states are the LRR (standardised to have a 
mean=0) and the BAF (ranges from 0 to 1).21 In an Illumina data analysis framework, X and 
Y values are derived for each marker from raw data in a five-step normalisation procedure 
implemented in Illumina’s software BeadStudio. Normalisation includes, among other steps, 
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removing outliers, background estimation and scale appropriation.22 R and theta (θ) values 
represent polar transformations of the intensities, and from this (and reference cluster 
locations) the LRR and BAF metrics are calculated. 
 
The R ratio obtained by PennCNV normalises the signal intensity from an individual to that 
of a reference sample population for each marker in the dataset. The R, or total signal 
intensity of both alleles at a SNP (R=X+Y) is calculated, after which LRR [log2 
(Rsubject/Rexpected)] can then be computed.
22 The Rexpected is computed from “canonical genotype 
clusters” detailed in.21 The theta value is calculated as θ = arctan (Y/X)/(π/2), and is meant to 
measure the relative allelic intensity ratio of alleles A and B.  
 
The transformation of R and θ into LRR and BAF aims to standardise signal level data across 
SNPs in order to allow ready comparisons while remaining sufficiently close to the raw data 
to carry relevant information for copy number quantification.23  
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RESULTS 
 
ARCS assays at KLK3 exon 3 
 
A total of 152 samples showed evidence of KLK3 deletion at exon 3 in at least one ARCS 
replicate. Among these deletions, 31 samples had both ARCS duplicates with higher values 
that 1.96SDs. A total of 18 samples had a failed replicate, and thus were removed from 
subsequent plate-specific statistical copy number assignment. A full list of samples with 
KLK3 deletions, in addition to samples with PCR failures, is provided  (Table 1). All of the 
deletions identified were single copy deletions. On the other hand, 116 samples were in 
accordance with a potential copy number gain in KLK3 at exon 3. Supplementary Figure 1 
shows results from one of the 1958 cohort DNA plates as an example of CNV calling defined 
by the 95% confidence interval.  
 
SNP array data (including BAF and LRR): WTCCC datasets. PennCNV  
 
CNV data from the analysis of the 1958BC data on PennCNV indicate the presence of 61 
heterozygous deletions encompassing KLK3 (freq= 2.13%) (Figure 1).  
 
The majority of KLK3 deletions in this cohort (86.5%) were less than 50 kb in length (median 
CNV length≈15.5 kb). LRR and BAF plots for one deletion detected by PennCNV are shown 
in (Supplementary Figure 2). A full list of deletions called in this cohort is 
provided(Appendix 1). 
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PennCNV identified three putative homozygous deletions (copy number = 0). Detailed 
manual inspection of log R Ratios and B allele frequency values were inconsistent with the 
occurrence of homozygous deletions. 
 
A subset of 44 deletions in KLK3 from the 1958BC data (≈61%) start at the SNP rs3760722 
in the promoter of the gene (Figure 2).  
 
These deletions range in length between 5.2 and 44 kb (mean=12.6 kb; median=6.8 kb; 
median no. of SNPs=18). Common endpoints were observed for these deletions, at rs6998 
(14 deletions), rs2735839 (13 deletions), rs6072 (4 deletions), rs2739472 and rs198972 (3 
deletions each) and rs198979 (2 deletions). Other common start points for deletions within 
this set include the SNPs rs2003783 (3 deletions), rs266881 (3 deletions), rs2271095 (2 
deletions). Common start points, end points and deletions are listed in Appendix 1. 
 
PennCNV analysis of the NBS cohort revealed a lower number of deletions compared to the 
1958 Cohort (27 deletions, freq= 0.99%) as shown  (Figure 3).  
 
 
Deletions within this set tend to be shorter (mean length≈26.6 Kb, median≈17.9 Kb) than the 
1958BC deletions (Table 2).  
 
 
All of the deletions detected were hemizygous (Appendix 1). As in the 1958BC dataset, 12 
deletions identified from the NBS cohort (44.8%) start at rs3760722; whereas 3 deletions 
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start at each one of the SNPs rs2659051, rs266849 and rs266881 (Figure 3). Common start 
points, end points and deletions are listed in Appendix 2. 
 
The two-fold difference (2.12% vs 0.99%) observed in the two samples tested is significant 
(P<0.05).  
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DISCUSSION 
 
To our knowledge, this study is the first report of the frequency of KLK3 deletions in the 
general population. We also found a number of KLK3 deletions with the same breakpoints, 
and others displaying one common breakpoint. Data from PennCNV estimates the frequency 
of KLK3 deletions within the 1958BC at 0.0213, and in the NBS cohort at 0.0099. These 
differences are significant, suggesting the existence of inter-population variability in the 
frequency of KLK3 deletions. An alternative explanation suggesting sample error could be 
argued from the fact that both estimates are in general agreement with our in vitro 
experiments for KLK3 deletions, estimated to occur at frequencies between 0.0081 and 
0.0398. This frequency is considerably higher than that of rare genetic variants and invites 
questions about the implications that KLK3 deletions could have on PCa diagnosis, 
monitoring and screening based on PSA. Assuming that the frequency of deletions observed 
in our population samples apply to other populations, one could predict the existence of 1 – 
2% of individuals that could potentially have a mistakenly low serum PSA concentration as a 
consequence of the deletions identified. All analysed samples are of Caucasian ethnicity, 
which minimises the occurrence of population stratification. 
 
CNV calling from ARCS data for samples from the 1958 cohort was based on a stringent 
measure: ARCS ratio values outside the confines of ±1.96SDs from the mean ratio of all 
samples per plate (a plate-specific attribute). One could envisage that the ARCS assays used 
in this study were adequately robust to capture CNV events in cluster analysis. ARCS is an 
accurate method –especially at low copy numbers- that avoids assumptions drawn from 
standard curve estimations, and offers a high-throughput, generic framework applicable to 
any CNV assay.12 
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In silico analyses presented in this work are informative for the detection of KLK3 deletions. 
With more than 1.2 million probes, the Illumina 1.2-M Duo used in genotyping the WTCCC2 
control sets is the most useful array for this purpose, as it offers the highest genomic 
resolution available to determine boundaries of deletions.  
 
All deletions were found in heterozygosis. However, in three instances, PennCNV assigned a 
zero copy number to three samples pointing to apparent homozygous deletions in KLK3. 
Careful inspection of LRR/BAF profiles of these samples did not confirm the occurrence of 
these apparent homozygous deletions in our population samples.  
 
Under the terms of data and material access agreements, it was not possible to link in vitro 
and in silico findings from this study. It has been suggested that biological confirmation is a 
necessary condition for validation of copy number events.14 Our in vitro and in silico 
estimates represent considerable agreement and independent biological confirmation of the 
frequency of KLK3 deletions in the UK population. Future studies are required to estimate the 
frequency of KLK3 deletions in other populations. 
 
Our study also enabled us to stratify KLK3 deletions by type and size. This approach 
identified a number of deletions that shared the same SNPs at the putative starting and ending 
points identified by PennCNV. Although it could be argued that the overall frequency of 
KLK3 deletions is relatively large, we have observed that the commonest single deletion 
observed in several individuals, was present in a frequency of 0.005. This frequency is lower 
than the threshold (0.01) previously suggested 24 to define common CNVs. The occurrence of 
what could possibly be the same deletion in several individuals from our UK sample suggests 
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the possibility of identity by descent and hence of transmission through the generations. 
However, it is also possible that they represent mutation hotspots, i.e. for recurrent similar 
deletions, (e.g. similar hemoglobin A, HBA, deletions).25 Neutral or deleterious effects of the 
deletions found in our study will need to be determined in future studies. 
 
As arrays tend to underestimate the size of CNVs, CNV breakpoints are better characterised 
by sequencing data. Arrays are limited in terms of resolution by the number and the genomic 
distribution of SNPs on the genotyping chip. The first and the last markers showing evidence 
of copy number in an array may still be within a deletion rather than representing its 
boundaries. Differences between sequence-detected and array-detected breakpoints can be 
used to evaluate the resolution and the reproducibility of array data.20  
 
The promoter SNP rs3760722 emerges as a plausible putative breakpoint at the start of KLK3 
deletions, as shown by the majority of deletions detected by PennCNV. The 3’UTR SNPs 
rs6998 and rs2735839 were found to represent the endpoint of numerous deletions as well. 
Interestingly, the latter SNPs were associated with serum PSA concentrations in several 
studies. Free serum PSA concentrations were associated with rs6998 26 and rs2735839 was 
also associated with PCa risk4 and serum PSA27-29 with studies suggesting that the association 
signal from this SNP is implied within a stronger signal from a coding SNP in exon 4 of the 
KLK3 gene; rs17632542.5, 28 The characterisation of well-defined CNVs in KLK3 would 
allow for testing associations between KLK3 deletions and serum PSA concentrations, and 
the recognition of putative breakpoints from SNP array data could prove a useful guide for 
KLK3 resequencing studies. 
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No data on serum PSA concentrations or PCa status are available from the 1958BC and NBS. 
Future studies are required in order to derive direct conclusions about the impact of KLK3 
deletions on the correlation between gene dose effect and serum PSA and PCa status. This 
will inform about the suitability of the PSA test in individuals carrying KLK3 deletions. 
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Figure legends 
Supplementary Figures 
 
Supplementary Figure 1. ARCS copy number analysis. 
 
ARCS ratios are derived from reference and target peak heights which are plotted on the x-
axis above, with fluorescence intensity on the y-axis. Samples with ARCS ratios in excess of 
2SDs from the mean ARCS ratio per run are classified as deletion candidates (e.g. sample 
10E), whereas samples with ratios lower the 2SDs are deemed duplication candidates (e.g. 
samples 12A and 3C).  
Supplementary Figure 2. Typical LRR and BAF profiles of a deletion detected by PennCNV. 
 
PennCNV uses LRR and BAF values to inform an HMM in order to assign copy numbers to 
deletions and duplications from SNP array data. This figure shows images of a deletion 
generated by the visualisation function in PennCNV. This script uses the statistical package R 
to generate an LRR/BAF profile for each sample. LRR plots are on the top panel, while BAF 
plots are on the bottom. The LRR/BAF values at each marker are represented by a dot. Each 
profile is segmented into three parts with left and right flanking regions showing normal copy 
number patterns and the discovered CNV in the middle demarcated between two grey vertical 
lines. The blue dots represent LRR/BAF values in regions with normal copy number, while 
the red dots correspond to the called CNV. The chromosomal positions are on the x-axis of 
each plot. With normal copy number, BAF values cluster near to 0.0, 0.5 and 1.0, whereas in 
a hemizygous deletion, BAF values cluster near 0.0 or 1.0, but not around 0.5 -as seen in the 
red dots between the vertical lines in the left image-. As for the LRR signals, these are 
normalised to 0.0, so that a deletion will show a decrease (typically around -0.5 for 
hemizygous deletions, but much lower for homozygous deletions). 
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Print Figures 
Figure 1. KLK3 heterozygous deletions in the 1958BC dataset.  
 
A snapshot of custom tracks generated by the UCSC genome browser. 61 single copy 
deletions were found in the 1958BC. Each deletion is represented by a track –in black-. 
(KLK3 is highlighted by the red box in the bottom panel. The scale bar at the top of the panel 
represents 100 kb.   
 
 
Figure 2. KLK3 deletions with a common start breakpoint in 1958BC.  
 
A total of 44 deletions were found to start at the SNP rs3760722 in the 1958BC dataset. 
Common endpoints are found at 6 different SNPs (annotated in red beside each group of 
tracks that share the same end). (KLK3 is highlighted by the red box in the bottom panel. The 
scale bar at the top of the panel represents 20 kb.   
 
Figure 3. KLK3 deletions in NBS A) Length. B) Common start breakpoints 
 
A) A total of 27 deletions were identified from the NBS dataset, with each deletion 
represented as a track –in black-. Several recurrent breakpoints could be identified visually. 
For example, the KLK3 promoter SNP rs3760722 marks the start of 12 deletions (KLK3 is 
highlighted by the red box in the lower panel of the figure, generated by the UCSC genome 
browser. The scale bar at the top of the panel represents 100 kb. 
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B) 12 deletions in the NBS dataset started at rs37607222. Four deletions were found to share 
putative start and end breakpoints. (KLK3 is highlighted by the red box in the lower panel of 
the figure, generated by the UCSC genome browser. The scale bar at the top of the panel 
represents 20 kb.  
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Table 1. A list of samples where KLK3 exon 3 was found deleted by ARCS.  
Deletions Failed ARCS 
2 reps 1 rep 2 reps 1 rep 
8H/12F/12H 9A/12G     
2H 2E/5G/12D     
8A 8H     
8A/9D 6H/9C     
2E 2A/3C/5E/7A     
11D 4C/7E/11A     
12F/12G 11F/12H     
  4G/6D/7B   5(A-H) /8A 
2E/5F/12H       
  8F/12H     
  7E     
  2F/2G/6B     
11B 8E/10G     
  2D   12F/12G/12H 
  9B/10C     
8G 2H/10D/11B     
  3B/3E/8B/9C     
  4G/5G/6F/7G   2H 
  9H/10H/11H/12E     
  2D/2G/11E     
  3E/10H/11G 2G   
  6F/10H/11G/11H     
  6E/8F/12E     
  2H/4H/5G/7G     
4G/12H 4D/6E/6F/12E     
2A 2F/11H/12H     
  3C/4D/4H/10C/11B     
  5B/10C/10F   12F/12G/12H 
3F/12H 12E/12G     
9E 7D/10A/10G   3E 
10E       
2F 8C/8G/12B     
  4E     
  3H/8A/8E     
  2A/4E/5G/9B/12A/12B     
        
2A 3A/8D/8H/9F     
4H       
  7H/11A/11H     
  11H/12E     
  2H/3C/8G     
8A/9D 7A/7F/9A/9B/10B/11H/12A     
12F 9G     
  2G/2H/5F/11A     
2A/12C 12D     
        
31 121 1 17 
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152 samples have shown evidence for a deletion in KLK3 exon 3 by at least one replicate in 
ARCS, including 31 samples where both replicates indicated a deletion. 18 samples were 
PCR failures. 
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Table 2. Results from the 1958BC and NBS datasets – PennCNV 
WTCCC2 
dataset 
Count (Freq)  
Median 
SNPs 
ROH Length (Kb) 
Shortest  Longest  Mean  Median  
1958 BC 61 ( 2.13%) 18 5.2  81.2  17.4  6.8  
NBS 27 ( 0.99%) 27 2.3  72.4  25.5  17.9  
 
 
